Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
FZD4 Biologics Sequence Review Report 2026: Frizzled-4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of FZD4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
FZD3 Biologics Sequence Review Report 2026: Frizzled-3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of FZD3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
FCRL6 Biologics Sequence Review Report 2026: Fc receptor-like protein 6 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of FCRL6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
FCRL5 Biologics Sequence Review Report 2026: Fc receptor-like protein 5 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of FCRL5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
FCRL2 Biologics Sequence Review Report 2026: Fc receptor-like protein 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of FCRL2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
FCRL1 Biologics Sequence Review Report 2026: Fc receptor-like protein 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of FCRL1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EGFL7 Biologics Sequence Review Report 2026: Epidermal growth factor-like protein 7 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of EGFL7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
EBI3 Biologics Sequence Review Report 2026: Interleukin-27 subunit beta Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of EBI3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
9 min read
Sintilimab in Malignant Mesothelioma of Peritoneum: NCT06543069 Clinical Landscape Report 2026
16 September 2026
NCT06543069 clinical landscape for Malignant Mesothelioma of Peritoneum: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
ISM-6331 in Mesothelioma, Malignant: NCT06566079 Clinical Landscape Report 2026
16 September 2026
NCT06566079 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
β-globin restored autologous hematopoietic stem cells (Hemogen Gene) in Beta-Thalassemia: TCTR20240910004 Clinical Landscape Report 2026
16 September 2026
TCTR20240910004 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Delandistrogene moxeparvovec in Muscular Dystrophy, Duchenne: NCT06597656 Clinical Landscape Report 2026
16 September 2026
NCT06597656 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.